Published results have shown 87% clinical response to non-invasive Transcranial Magnetic Stimulation with neuroplastic medications.Clinical ...

SHINKEI THERAPEUTICS RECEIVES FDA CLEARANCE TO PROCEED WITH PHASE 1 CLINICAL TRIAL FOR MR-101 AND COMPLETES PHASE 2 ...

Axsome Therapeutics (NASDAQ:AXSM) executives highlighted accelerating commercial momentum, a near-term regulatory catalyst, ...

10 natural sleep powders for a refreshing night’s rest without melatonin grogginess - When sleep feels elusive, non-melatonin ...

Detailed price information for Mira Pharmaceuticals Inc (MIRA-Q) from The Globe and Mail including charting and trades.

Some serious brain disorders begin with symptoms that are easy to misinterpret. A person may become confused, forgetful or paranoid and be treated for mental illness before doctors realize the ...

The bipolar depression market is anticipated to increase during the forecast period (2026--2036), owing to the rise in the launch of emerging therapies such as Azetukalner (Xenon Pharmaceuticals), ...

对于正在与重度抑郁症（MDD）抗争的患者而言，等待药物起效的过程往往充满煎熬。传统抗抑郁药物通常需要4-6周才能显现疗效，这段“治疗空窗期”对许多深陷痛苦的患者来说，是巨大的身心挑战。

Detailed price information for Nrx Pharmaceuticals Inc (NRXP-Q) from The Globe and Mail including charting and trades.